You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The CVS-Tempus partnership aims to streamline the cancer care process for patients from the point of prescribing onwards and connect patients with local trials.
A preliminary analysis lends some support to covering NIPS for pregnancies beyond high-risk, and some payors have expanded coverage.
The company announced positive coverage decisions from Palmetto GBA, 14 BCBS plans, and Aetna.
Starting Feb. 15, Aetna members will be able to access NxGen MDx's genetic screening and noninvasive prenatal testing as an in-network benefit.
It was a rough year for biotech stocks — the Nasdaq Biotech Index fell 22 percent even as the Dow gained 13 percent and the Nasdaq gained 8 percent.
The new agreement brings Interpace's total insurance coverage for its thyroid assays to approximately 200 million patients.
The test differentiates benign thyroid nodules from cancerous ones.
NEW YORK (GenomeWeb) – CardioDx today announced that Aetna has established a clinical policy for the Corus CAD gene expression test for coronary artery disease.
Insurer Aetna last month released a clinical policy bulletin providing an assessment of various available molecular-based cancer diagnostics and markers.
While Working with FDA, 23andMe Offers Customers No Timeline for Reporting Health-related Results
Novamax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.